Literature DB >> 23498873

Total hip arthroplasty followed by traction and delayed reduction for Crowe IV developmental dysplasia of the hip.

Brody A Flanagin1, Craig H Dushey, Lee E Rubin, Kristaps J Keggi.   

Abstract

Hip dislocation secondary to developmental dysplasia of the hip is a debilitating condition. Total hip arthroplasty has proven successful in improving pain, restoring joint function, and correcting leg length discrepancies in this select population. Various techniques have been developed to address the increased complexity inherent to the reconstruction of the severely dysplastic hip. Despite this, femoral and/or sciatic nerve palsy remains a potential catastrophic complication after surgery, with reported rates up to five times that in the general population. We present three cases using a previously unreported technique for performing primary total hip arthroplasty via an anterior approach for Crowe IV hip dysplasia. The goal of this technique is to minimize the risk of postoperative nerve palsy following reconstruction of the severely dysplastic hip. A brief discussion of our technique and the topic of nerve dysfunction after total hip arthroplasty for developmental dysplasia of the hip follows.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23498873     DOI: 10.1016/j.arth.2012.11.019

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  Clinical evaluation of direct anterior approach total hip arthroplasty for severe developmental dysplasia of the hip.

Authors:  Zaiyang Liu; Courtney D Bell; Alvin C Ong; Jun Zhang; Jie Li; Yuan Zhang
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

Review 2.  Total Hip Arthroplasty for Crowe Type IV Hip Dysplasia: Surgical Techniques and Postoperative Complications.

Authors:  Xiao-Tong Shi; Chao-Feng Li; Yu Han; Ya Song; Shu-Xuan Li; Jian-Guo Liu
Journal:  Orthop Surg       Date:  2019-11-22       Impact factor: 2.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.